Physician profile
Gary Ritten
NPI 1437211307
$2,134.27
in general payments reported to CMS, 2019-2025
36 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $231 · 2021: $330 · 2022: $246 · 2023: $226 · 2024: $282 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.34 | 2019-2025 | Ubrelvy |
| Novo Nordisk INC | $223.98 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Lilly USA, LLC | $153.89 | 2020-2025 | Zepbound, Mounjaro, Emgality |
| Amarin Pharma, INC. | $119.43 | 2020-2021 | |
| Daiichi Sankyo INC. | $113.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.51 | 2020-2024 | Synjardy, Jardiance |
| Exact Sciences Corporation | $96.95 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $94.25 | 2019-2024 | Proclaim |
| Amgen INC. | $88.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $83.01 | 2020-2022 | |
| Glaxosmithkline, LLC. | $74.18 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $71.29 | 2019-2024 | |
| Dexcom, INC. | $63.21 | 2024-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $53.69 | 2024-2025 | Omnipod |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.97 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.53 | 2025 | Caplyta |
| Pfizer INC. | $37.39 | 2020 | |
| Pacira Therapeutics, INC. | $34.96 | 2021 | |
| Biogen, INC. | $28.95 | 2025 | Zurzuvae |
| Phathom Pharmaceuticals, INC. | $27.96 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $27.49 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $25.79 | 2019 | |
| Gilead Sciences, INC. | $25.28 | 2022-2023 | Epclusa |
| Lundbeck LLC | $23.82 | 2024 | Rexulti |
| Seqirus USA INC | $21.93 | 2025 | Flucelvax, Fluad |
| Biohaven Pharmaceuticals, INC. | $20.13 | 2021 | |
| Myovant Sciences INC. | $19.90 | 2022 | |
| Axonics, INC. | $17.60 | 2022 | |
| Ucb, INC. | $16.34 | 2019 | |
| Shield Therapeutics INC | $15.68 | 2024 | |
| Grifols USA, LLC | $15.50 | 2020 | |
| Coopersurgical, INC. | $15.09 | 2020 | |
| Bioventus LLC | $12.82 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.72 | 2021 | |
| Organon LLC | $12.57 | 2022 | |
| Hikma Pharmaceuticals USA | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Ritten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.